US 12,440,498 B2
Combination of diltiazem and viral polymerase inhibitors
Olivier Terrier, Lyons (FR); Manuel Rosa-Calatrava, Lyons (FR); Guy Boivin, Quebec (CA); Mario-Andres Pizzorno, Lyons (FR); and Blandine Padey, Lyons (FR)
Assigned to UNIVERSITE CLAUDE BERNARD LYON 1, Villeurbanne (FR); INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), Paris (FR); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), Paris (FR); UNIVERSITE LAVAL, Quebec (CA); and ECOLE NORMALE SUPERIEURE DE LYON, Lyons (FR)
Appl. No. 17/792,403
Filed by UNIVERSITE CLAUDE BERNARD LYON 1, Villeurbanne (FR); INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), Paris (FR); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), Paris (FR); UNIVERSITE LAVAL, Quebec (CA); and ECOLE NORMALE SUPERIEURE DE LYON, Lyons (FR)
PCT Filed Jan. 12, 2021, PCT No. PCT/FR2021/050049
§ 371(c)(1), (2) Date Jul. 13, 2022,
PCT Pub. No. WO2021/144528, PCT Pub. Date Jul. 22, 2021.
Claims priority of application No. 2000255 (FR), filed on Jan. 13, 2020.
Prior Publication US 2023/0075092 A1, Mar. 9, 2023
Int. Cl. A61K 31/554 (2006.01); A61K 9/00 (2006.01); A61K 31/5383 (2006.01); A61K 45/06 (2006.01); A61P 31/16 (2006.01)
CPC A61K 31/554 (2013.01) [A61K 9/0073 (2013.01); A61K 31/5383 (2013.01); A61K 45/06 (2013.01); A61P 31/16 (2018.01)] 25 Claims
 
1. A combination of diltiazem and at least one viral polymerase inhibitor compound selected from the group consisting of: baloxavir marboxil, pimodivir, RO-7 and CC-42344.